Optimizing FLT3 Inhibitor Use in Adult Acute Myeloid Leukemia with FLT3 Mutations Using Proteomics

被引：0
|
作者：
Magalhaes, Eduardo Sabino [1 ]
Hubner, Stefan [2 ]
Brown, Brandon D. [3 ]
Qiu, Yihua [4 ]
Kornblau, Steven M. [4 ]
机构：
[1] Univ Med Ctr Groningen, Dept Ageing Biol, ERIBA, Groningen, Netherlands
[2] Univ Texas Med Branch UTMB, John Sealy Sch Med, Galveston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Pediat, Houston, TX USA
[4] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186508
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Masamichi Mori
    Naoki Kaneko
    Yoko Ueno
    Masaki Yamada
    Ruriko Tanaka
    Rika Saito
    Itsuro Shimada
    Kenichi Mori
    Sadao Kuromitsu
    Investigational New Drugs, 2017, 35 : 556 - 565
  • [32] Correction to: Gilteritinib: a novel FLT3 inhibitor for acute myeloid leukemia
    Juanjuan Zhao
    Yongping Song
    Delong Liu
    Biomarker Research, 7
  • [33] FLT3 mutations in myeloid sarcoma
    Ansari-Lari, MA
    Yang, CF
    Tinawi-Aljundi, R
    Cooper, L
    Long, P
    Allan, RH
    Borowitz, MI
    Berg, KD
    Murphy, KM
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (06) : 785 - 791
  • [34] OTS167 Inhibits FLT3 Expression in FLT3 Mutant Acute Myeloid Leukemia
    Eisfelder, Bartholomew
    Wynne, Joseph
    Colton, Margert
    Cheng, Jason
    Odenike, Olatoyosi
    Alachkar, Houda
    Stock, Wendy
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S239 - S240
  • [35] Differential flt3 mutational status in acute myeloid leukemia predicts sensitivity to flt3 inhibitor gilteritinib in vitro and in vivo
    John, Bincy
    Sundaramoorthy, Pasupathi
    Rainbolt, Elizabeth
    Wong, Andrew
    Ward, Zachary
    Avery, Justin
    Todd, Savannah
    Kidder, Shasta
    Gietl, Diana
    Hall, Chassidy
    Harris, David
    CANCER RESEARCH, 2023, 83 (07)
  • [36] Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
    Mori, Masamichi
    Kaneko, Naoki
    Ueno, Yoko
    Yamada, Masaki
    Tanaka, Ruriko
    Saito, Rika
    Shimada, Itsuro
    Mori, Kenichi
    Kuromitsu, Sadao
    INVESTIGATIONAL NEW DRUGS, 2017, 35 (05) : 556 - 565
  • [37] Concomitant targeting of FLT3 and BTK overcomes FLT3 inhibitor resistance in acute myeloid leukemia through the inhibition of autophagy
    Zhang, Weiguo
    Yu, Guopan
    Zhang, Hongying
    Basyal, Mahesh
    Ly, Charlie
    Yuan, Bin
    Ruvolo, Vivian
    Piya, Sujan
    Bhattacharya, Seemana
    Zhang, Qi
    Borthakur, Gautam
    Battula, Venkata L.
    Konopleva, Marina
    Rice, William G.
    Andreeff, Michael
    HAEMATOLOGICA, 2023, 108 (06) : 1500 - 1514
  • [38] FLT3 Inhibitors for Treating Acute Myeloid Leukemia
    Hassanein, Mona
    Almahayni, Muhamad H.
    Ahmed, Syed O.
    Gaballa, Sameh
    El Fakih, Riad
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2016, 16 (10): : 543 - 549
  • [39] FLT3 inhibitors for the treatment of acute myeloid leukemia
    Metzelder S.
    Röllig C.
    best practice onkologie, 2018, 13 (4) : 182 - 190
  • [40] FLT3 Inhibitors in Acute Myeloid Leukemia: An Update
    Stone, R. M.
    ANNALS OF HEMATOLOGY, 2011, 90 : S70 - S72
12345